Drugs / Bupropion
Bupropion
also known as
bupropion-SR · Bupropion HCl · bupropion hydrochloride · Wellbutrin · Zyban · BUP · Bupropion XL · WELLBUTRIN SR · +22 more
Small molecule targets TNF
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Mysimba | — | 2015-03-26 | europa.eu ↗ |
| Label expansion | US (FDA) | APLENZIN | — | 2012-08-15 | fda.gov ↗ |
| Label expansion | US (FDA) | WELLBUTRIN XL | — | 2006-06-12 | fda.gov ↗ |
| Label expansion | US (FDA) | WELLBUTRIN SR | — | 2001-06-11 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | ZYBAN | — | 1999-09-10 – 2001-02-07 | fda.gov ↗ |
| Approved | US (FDA) | WELLBUTRIN | — | 1985-12-30 | fda.gov ↗ |
Trials 264 · started per year
today
US approved 1985
EU approved 2015
1
2
4
4
2
7
6
11
24
18
7
12
6
5
2
1
6
11
12
8
11
13
4
10
16
13
5
7
8
14
12
2
1985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT04553263 | Jun 2023 → Jan 2025 | attention deficit-hyperactivity disorder, cognitive disorder, substance abuse | University of California, Los Angeles | Withdrawn | No outcome recorded |
| Phase 0 | NCT03623711 | Aug 2018 → Dec 2022 | major depressive disorder | Yuqi Cheng | Unknown | No outcome recorded |
| Phase 0 | NCT03420469 | Jun 2018 → May 2019 | thyroid hormone metabolism, abnormal | Indiana University | Completed | No outcome recorded |
| Phase 0 | NCT02582008 | Jan 2016 → Oct 2018 | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, nasopharyngeal carcinoma, oral cavity squamous cell carcinoma +1 | Wake Forest University Health Sciences | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT01739192 | Jan 2013 → Dec 2017 | cocaine dependence | Craig Rush | Completed | No outcome recorded |
| Phase 160 trials | ||||||
| Phase 1 | NCT07224087 | Oct 2026 → Dec 2027 expected | obesity disorder | Medical University of South Carolina | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07584434 | May 2026 → Mar 2027 expected | narcolepsy 1 | Vertex Pharmaceuticals Incorporated | Recruiting | No outcome recorded |
| Phase 1 | NCT07269873 | Mar → Dec 2026 expected | — | BioCorRx Pharmaceuticals Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT07223671 | Dec 2025 → Feb 2026 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT07259330 | Oct 2025 → Mar 2026 | — | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT07235748 | Oct → Dec 2025 | — | Servier | Completed | No outcome recorded |
| Phase 1 | NCT06930872 | Jun → Oct 2025 | — | Harmony Biosciences Management, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06973005 | May → Jul 2025 | liver disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT07824193 | Jan → Apr 2025 | — | Epygenix | Completed | No outcome recorded |
| Phase 1 | NCT06679413 | Dec 2024 → Jun 2025 | — | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06564441 | Oct 2024 → Dec 2025 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06374290 | Jul → Dec 2024 | — | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT06367153 | May → Aug 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05932277 | Jun → Sep 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05981365 | Apr → Oct 2023 | sickle cell disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05334108 | Apr → Aug 2022 | — | Emalex Biosciences Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04814498 | May → Sep 2021 | — | Blade Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04464577 | Apr → Jun 2021 | — | Bristol-Myers Squibb | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT04764851 | Feb → Apr 2021 | — | Emalex Biosciences Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04757532 | Dec 2020 → Mar 2021 | — | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 1 | NCT04457180 | Nov 2020 → May 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04643249 | Nov → Dec 2020 | mitochondrial disease | Abliva AB | Completed | No outcome recorded |
| Phase 1 | NCT04526210 | Oct 2020 → May 2021 | Wilson disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04664725 | Jun 2020 → Jan 2021 | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04709094 | Jul → Oct 2019 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03864042 | Jan 2018 → Jul 2022 | cancer, metastatic melanoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03301207 | Oct 2017 → Jul 2018 | B-cell chronic lymphocytic leukemia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03058419 | Mar → May 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03234699 | Feb → Jul 2017 | — | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02698553 | May → Jun 2016 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02735603 | Apr → Jul 2016 | early repolarization associated with ventricular fibrillation | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02745912 | Apr → Jun 2016 | — | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02568176 | Oct 2015 → Feb 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02473627 | May → Jul 2015 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT02369172 | Feb → Apr 2015 | — | Maruho Europe Limited | Completed | No outcome recorded |
| Phase 1 | NCT02305901 | Dec 2014 → Mar 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02391688 | Nov 2014 → Apr 2015 | — | Jules Desmeules | Completed | No outcome recorded |
| Phase 1 | NCT02048917 | Jul 2014 → May 2019 | head and neck cancer, lung cancer | University of Kentucky | Completed | No outcome recorded |
| Phase 1 | NCT02085967 | Feb → Apr 2014 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01769768 | Apr 2013 → Aug 2016 | neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01771874 | Jan → May 2013 | substance-related disorder | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT01731067 | Nov 2012 → May 2013 | — | Jules Desmeules | Completed | No outcome recorded |
| Phase 1 | NCT01635972 | Jun → Jul 2012 | — | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00625859 | Jan → Apr 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00504413 | Jul 2007 → Jan 2011 | substance-related disorder | University of Washington | Unknown | No outcome recorded |
| Phase 1 | NCT00865111 | Mar → Apr 2006 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00864981 | Sep → Oct 2005 | depressive disorder | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT00133757 | Jun 2005 → May 2006 | nicotine dependence | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 1 | NCT00865371 | Sep 2004 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00865410 | Aug → Sep 2004 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00865462 | Jul 2004 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00863941 | Jun → Jul 2004 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00861939 | Mar → Apr 2004 | depressive disorder | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT03920319 | Jan 2004 → Dec 2005 | nicotine dependence | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1 | NCT00136747 | Jan 2004 → May 2009 | nicotine dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1 | NCT00069459 | Sep 2003 → Jun 2004 | depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00040040 | Jun 2002 → Sep 2003 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Unknown | No outcome recorded |
| Phase 1 | NCT00018187 | Nov 1998 → Jun 2001 | — | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 1 | NCT00883155 | Oct 1998 | — | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT00000276 | Sep 1994 → Aug 1999 | cocaine abuse | Yale University | Terminated | No outcome recorded |
| Phase 1/210 trials · 1 met primary · 1 missed | ||||||
| Phase 1/2 | NCT07398404 | Sep 2026 → Dec 2030 expected | obesity disorder | Medical University of South Carolina | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07596212 | Jul 2026 → Jul 2028 expected | hormone receptor-positive breast cancer, hypoactive sexual desire disorder | University of Illinois at Chicago | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06609343 | Jun → Nov 2026 expected | end stage renal failure | The University of Texas Health Science Center at San Antonio | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05976646 | Sep 2023 → Jul 2025 | opiate dependence | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1/2 | NCT01982643 | Nov 2013 → Feb 2015 | methamphetamine dependence | Walter Ling | Completed | No outcome recorded |
| Phase 1/2 | NCT01857596 | Apr 2013 → Oct 2014 | hypoactive sexual desire disorder | S1 Biopharma, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01219673 | Mar 2013 → Jan 2014 | head and neck cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01032018 | Jan 2010 → Jan 2012 | acute coronary syndrome, depressive disorder | Columbia University | Completed | Met primary |
| Phase 1/2 | NCT00129246 | Dec 2004 → Dec 2005 | nicotine dependence | Yale University | Completed | Missed primary |
| Phase 1/2 | NCT00593099 | Apr 2004 → Jun 2006 | bipolar disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 235 trials · 2 met primary · 4 missed | ||||||
| Phase 2 | NCT07810738 | Oct 2026 → Mar 2029 expected | major depressive disorder | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07523048 | Nov 2025 → Jul 2026 overdue | major depressive disorder | Roger McIntyre | Recruiting | No outcome recorded |
| Phase 2 | NCT07171112 | Nov 2025 → Jul 2026 | acute pancreatitis, chronic pancreatitis, nicotine dependence, recurrent acute pancreatitis | Mayo Clinic | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT06517797 | Oct 2025 → Jun 2027 expected | obesity disorder | S1 Biopharma, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03326128 | Sep 2021 → Jul 2023 | nicotine dependence | University of Southern California | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04971291 | Apr → Jul 2021 | major depressive disorder | Axsome Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04634071 | Jan 2021 → Jan 2026 | cancer-related condition | Joseph Valentino, MD | Completed | No outcome recorded |
| Phase 2 | NCT04437485 | Oct 2020 → Aug 2022 | dysthymic disorder, major depressive disorder, prediabetes syndrome, type 2 diabetes mellitus | Indiana University | Completed | Missed primary |
| Phase 2 | NCT04634669 | Sep 2020 → Feb 2022 | major depressive disorder | Axsome Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04167306 | Mar 2019 → Dec 2022 | alcohol dependence | Vastra Gotaland Region | Completed | Met primary |
| Phase 2 | NCT02501265 | Jun 2017 → Jul 2020 | nicotine dependence | Duke University | Completed | Met primary |
| Phase 2 | NCT03180294 | May 2017 → Feb 2021 | breast carcinoma, cervical carcinoma, ovarian carcinoma, uterine corpus cancer +2 | NRG Oncology | Completed | Missed primary |
| Phase 2 | NCT02842073 | Nov 2016 → Dec 2017 | alcohol-related disorders | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT02458690 | Jul 2015 → Aug 2019 | coronary artery disorder, dysthymic disorder, major depressive disorder, stroke disorder | Indiana University | Completed | Missed primary |
| Phase 2 | NCT01286402 | Apr 2011 → Oct 2012 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2 | NCT00994448 | Oct 2009 → Dec 2011 | amphetamine abuse | University of California, Los Angeles | Completed | Missed primary |
| Phase 2 | NCT00711477 | Sep 2008 → Jun 2010 | obesity disorder | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00742573 | Aug 2008 → Jan 2014 | major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT00624858 | Jan 2008 → Jul 2009 | depressive disorder | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00563563 | Oct 2007 → Sep 2008 | nicotine dependence, obesity disorder | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00580853 | Apr 2007 → Oct 2016 | — | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00330616 | May 2006 → Nov 2007 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00534001 | Jan 2006 → May 2008 | cervical cancer, esophageal cancer, gastric cancer, head and neck cancer +7 | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00364871 | Apr 2005 → Mar 2007 | obesity disorder | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00135512 | Dec 2004 → May 2007 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00330187 | Mar 2004 → Jul 2009 | nicotine dependence | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT00218231 | Jan 2004 → Aug 2006 | nicotine dependence, schizophrenia | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00136760 | Sep 2003 → Mar 2009 | nicotine dependence, schizophrenia | Brown University | Completed | No outcome recorded |
| Phase 2 | NCT00086411 | Sep 2003 → Apr 2008 | nicotine dependence | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT00069251 | Jul 2003 → Jun 2005 | methamphetamine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT01875172 | Oct 2001 → Jan 2004 | pregnancy disorder | Watching Over Mothers & Babies Foundation | Completed | No outcome recorded |
| Phase 2 | NCT00124683 | Sep 2001 → May 2007 | nicotine dependence, schizophrenia | National Institute on Drug Abuse (NIDA) | Completed | Mixed |
| Phase 2 | NCT00227812 | Apr 2001 → Dec 2005 | cocaine dependence, major depressive disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00249509 | Sep 2000 → Sep 2004 | hallucinogen abuse | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00001483 | Jun 1995 → May 2002 | bipolar disorder, depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2/315 trials · 2 met primary | ||||||
| Phase 2/3 | NCT04605081 | Jan 2022 → May 2027 expected | eating disorder, obesity disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04662801 | Aug 2021 → Sep 2022 | obesity disorder | Yale University | Completed | No outcome recorded |
| Phase 2/3 | NCT04599478 | Jun 2021 → Dec 2025 overdue | eating disorder, obesity disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04747314 | Mar 2021 → Nov 2024 | anxiety, chronic pain syndrome | Ajay Wasan, MD, Msc | Completed | No outcome recorded |
| Phase 2/3 | NCT04501016 | Sep 2020 → Aug 2021 overdue | nicotine dependence | Iowa City Veterans Affairs Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT03946111 | Aug 2019 → Dec 2024 | binge eating disorder, obesity disorder | Yale University | Completed | No outcome recorded |
| Phase 2/3 | NCT03539900 | Apr 2018 → Apr 2022 | binge eating disorder | Yale University | Completed | Mixed |
| Phase 2/3 | NCT03047005 | Aug 2017 → Dec 2021 | binge eating disorder, obesity disorder | Yale University | Completed | Mixed |
| Phase 2/3 | NCT03045341 | Feb 2017 → Jul 2021 | binge eating disorder, obesity disorder | Yale University | Completed | Met primary |
| Phase 2/3 | NCT00621517 | Feb 2008 → Jul 2009 | restless legs syndrome | East Tennessee State University | Completed | No outcome recorded |
| Phase 2/3 | NCT00419731 | Nov 2006 → Feb 2010 | nicotine dependence | University of Minnesota | Unknown | Met primary |
| Phase 2/3 | NCT00507728 | Dec 2005 → Dec 2019 | nicotine dependence | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00414167 | Dec 2005 → Mar 2011 | binge eating disorder, obesity disorder | Yale University | Completed | No outcome recorded |
| Phase 2/3 | NCT00126373 | May 2005 → Mar 2006 | Crohn disease | Altschuler, Eric, M.D. | Completed | No outcome recorded |
| Phase 2/3 | NCT00080158 | Mar 2004 → Jun 2007 | depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 342 trials · 11 met primary · 3 missed | ||||||
| Phase 3 | NCT07806279 | Oct 2026 → Dec 2030 expected | metabolic syndrome X, obesity disorder | Uppsala University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07766655 | Aug 2026 → Dec 2027 expected | — | Axsome Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05603104 | Apr 2025 → Jun 2028 expected | bipolar depression, major depressive disorder, schizophrenia | Dr. Inge Winter | Recruiting | No outcome recorded |
| Phase 3 | NCT06958692 | Apr 2025 → Sep 2026 overdue | major depressive disorder | CSPC Ouyi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05973786 | Feb 2025 → Jun 2028 expected | bipolar depression | Dr. Inge Winter | Recruiting | No outcome recorded |
| Phase 3 | NCT06233799 | Jul 2024 → Oct 2026 expected | amphetamine abuse, methamphetamine dependence | National Institute on Drug Abuse (NIDA) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05646862 | Jun 2023 → Nov 2026 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT05157698 | Jan 2022 → May 2026 | obesity disorder | Yale University | Completed | No outcome recorded |
| Phase 3 | NCT05205811 | Dec 2021 → Jun 2025 | — | Rose Research Center, LLC | Completed | No outcome recorded |
| Phase 3 | NCT04947553 | Jun 2021 → Dec 2024 | Alzheimer disease | Axsome Therapeutics, Inc. | Completed | Met primary |
| Phase 3 | NCT03342027 | Aug 2020 → Jul 2023 | HIV infectious disease | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 3 | NCT04388319 | May 2020 → Jun 2021 | — | Rose Research Center, LLC | Completed | No outcome recorded |
| Phase 3 | NCT04039022 | Jul 2019 → Oct 2020 | major depressive disorder | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03996265 | Jun 2019 → Jul 2026 overdue | cancer, hematopoietic and lymphoid system neoplasm | University of Rochester NCORP Research Base | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04019704 | Jun → Nov 2019 | major depressive disorder | Axsome Therapeutics, Inc. | Completed | Met primary |
| Phase 3 | NCT03897439 | May 2019 → Nov 2021 | — | University of Kansas Medical Center | Completed | Missed primary |
| Phase 3 | NCT03078075 | May 2017 → Jul 2019 | methamphetamine dependence | University of Texas Southwestern Medical Center | Completed | Met primary |
| Phase 3 | NCT02191397 | Feb 2015 → Oct 2016 | major depressive disorder | GlaxoSmithKline | Completed | Missed primary |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT01764386 | Feb 2013 → Sep 2014 | obesity disorder | Orexigen Therapeutics, Inc | Completed | Met primary |
| Phase 3 | NCT01601704 | Jun 2012 → Aug 2015 | obesity disorder | Orexigen Therapeutics, Inc | Terminated | No outcome recorded |
| Phase 3 | NCT00567255 | Dec 2007 → Jun 2009 | obesity disorder | Orexigen Therapeutics, Inc | Completed | Met primary |
| Phase 3 | NCT00532779 | Oct 2007 → May 2009 | obesity disorder | Orexigen Therapeutics, Inc | Completed | Met primary |
| Phase 3 | NCT00587769 | Jul 2007 → Jul 2008 | nicotine dependence | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00474630 | May 2007 → Jun 2009 | obesity disorder, type 2 diabetes mellitus | Orexigen Therapeutics, Inc | Completed | Met primary |
| Phase 3 | NCT00456521 | Mar 2007 → Dec 2008 | obesity disorder | Orexigen Therapeutics, Inc | Completed | Met primary |
| Phase 3 | NCT00296517 | Jan 2006 → Mar 2008 | depressive disorder | GlaxoSmithKline | Completed | Missed primary |
| Phase 3 | NCT00296933 | Dec 2005 → ? | major depressive disorder | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT00125957 | Aug 2005 → Jan 2010 | major depressive disorder | Mclean Hospital | Completed | Mixed |
| Phase 3 | NCT00304707 | Apr 2005 → Feb 2010 | alcohol-related disorders | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 3 | NCT00179244 | Jul 2004 → Apr 2005 | major depressive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 3 | NCT00093288 | Jun 2004 → Oct 2005 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00108537 | Oct 2003 → Sep 2005 | nicotine dependence | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 3 | NCT00414180 | Aug 2003 → May 2005 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00064467 | Jun 2003 → May 2005 | epilepsy, major depressive disorder | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00051259 | Jan 2003 → Jun 2004 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00051272 | Jan 2003 → Jun 2004 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00048360 | Oct 2002 → Jun 2003 | attention deficit-hyperactivity disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00046241 | Sep 2002 → Jun 2003 | seasonal affective disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00033592 | Feb 2002 → Jul 2006 | lung cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00086385 | Sep 2001 → Mar 2009 | nicotine dependence | University of California, San Francisco | Completed | Met primary |
| Phase 3 | NCT00344695 | ? → Apr 2003 | nicotine dependence | University of Arizona | Completed | Met primary |
| Phase 472 trials · 4 met primary · 4 missed | ||||||
| Phase 4 | NCT07835555 | Sep 2027 → Sep 2030 expected | HIV infectious disease, nicotine dependence | Yale University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT02129751 | Jul 2027 → Jul 2030 expected | major depressive disorder | Bausch Health Americas, Inc. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07832084 | Nov 2026 → Apr 2027 expected | obesity disorder | Jing Luo | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07213466 | Jan 2026 → Feb 2028 expected | bipolar I disorder, bipolar II disorder, obesity disorder, schizoaffective disorder | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT06620562 | Jun 2025 → Jun 2028 expected | morbid obesity | Laval University | Recruiting | No outcome recorded |
| Phase 4 | NCT06605703 | Sep 2024 → Feb 2026 | obesity disorder | WW International Inc | Completed | No outcome recorded |
| Phase 4 | NCT06809166 | Jul 2024 → Jan 2026 overdue | obesity disorder | The Royal's Institute of Mental Health Research | Recruiting | No outcome recorded |
| Phase 4 | NCT06254001 | Jan 2024 → Jan 2025 | nicotine dependence, substance withdrawal syndrome | National Institute of Respiratory Diseases, Mexico | Unknown | No outcome recorded |
| Phase 4 | NCT05919797 | Jun 2023 → Jun 2027 expected | obesity disorder | Columbia University | Recruiting | No outcome recorded |
| Phase 4 | NCT05351606 | May 2023 → Jan 2025 | nicotine dependence | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT05537584 | Sep 2022 → Aug 2025 | major depressive disorder | Mclean Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05277207 | May 2022 → Sep 2023 | nicotine dependence | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT04587843 | Apr 2021 → Dec 2023 | obesity disorder | St. Joseph's Healthcare Hamilton | Unknown | No outcome recorded |
| Phase 4 | NCT04589130 | Feb 2021 → Dec 2023 | obesity disorder | St. Joseph's Healthcare Hamilton | Unknown | No outcome recorded |
| Phase 4 | NCT04352101 | Sep 2020 → Jul 2022 | major depressive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT04604509 | Aug 2020 → Dec 2028 expected | — | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 4 | NCT04490057 | Jul 2020 → Oct 2024 | nicotine dependence | Yale University | Completed | Missed primary |
| Phase 4 | NCT04098874 | Jan 2020 → Jul 2026 overdue | — | University of Minnesota | Recruiting | No outcome recorded |
| Phase 4 | NCT04135937 | Nov 2019 → Jul 2021 | HIV infectious disease | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT05531591 | Aug 2019 → Jul 2024 | cognitive impairment with or without cerebellar ataxia, dementia, major depressive disorder | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 4 | NCT03993457 | Jul 2019 → Mar 2022 | depressive disorder | University of Texas Southwestern Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT03219008 | Aug 2017 → Dec 2019 | major depressive disorder | Shanghai Mental Health Center | Unknown | Missed primary |
| Phase 4 | NCT03148509 | Jun 2017 → Dec 2019 | — | Peking University | Unknown | No outcome recorded |
| Phase 4 | NCT02960763 | Feb 2017 → Sep 2020 | major depressive disorder | Washington University School of Medicine | Completed | Mixed |
| Phase 4 | NCT02736474 | May 2016 → Jul 2018 | obesity disorder, schizophrenia | Shanghai Mental Health Center | Completed | No outcome recorded |
| Phase 4 | NCT02238977 | Mar 2016 → Mar 2018 | end stage renal failure, major depressive disorder | University of Arkansas | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02616315 | Feb 2016 → Oct 2017 | — | Takeda | Withdrawn | No outcome recorded |
| Phase 4 | NCT02638129 | Jan → Jun 2016 | cardiovascular disorder, obesity disorder | Orexigen Therapeutics, Inc | Terminated | No outcome recorded |
| Phase 4 | NCT02291666 | Apr 2015 → Jul 2019 | type 2 diabetes mellitus | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 4 | NCT02209597 | Jun 2014 → Aug 2016 | major depressive disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02173886 | Jun 2014 → Feb 2015 | — | North Dakota State University | Completed | No outcome recorded |
| Phase 4 | NCT01583023 | Apr 2014 → Apr 2015 | bipolar disorder | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
| Phase 4 | NCT02676375 | Jan 2014 → Jun 2016 | schizophrenia | Brentwood Biomedical Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01916824 | Aug 2013 → Dec 2015 | major depressive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02162862 | Jul 2013 → Jun 2016 | inflammatory bowel disease, sleep disorder | Eva Szigethy | Completed | No outcome recorded |
| Phase 4 | NCT02401256 | Jul 2013 → May 2016 | — | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT01716221 | Oct 2012 → Mar 2013 | Friedreich ataxia | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT01574703 | May 2012 → Jul 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT01477931 | Nov 2010 → Jul 2011 | major depressive disorder | Chi-Un Pae | Completed | No outcome recorded |
| Phase 4 | NCT00962988 | Dec 2009 → Apr 2015 | cerebrovascular disorder | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01015170 | Oct 2009 → Oct 2015 | nicotine dependence | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 4 | NCT00991081 | Jul 2009 → Mar 2011 | — | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT01541475 | Mar 2009 → Jan 2011 | major depressive disorder | Ewha Womans University | Completed | No outcome recorded |
| Phase 4 | NCT00846339 | Nov 2008 → Mar 2009 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00666978 | Dec 2007 → Jun 2010 | cervical cancer, esophageal cancer, gastric cancer, head and neck cancer +7 | Lisa Sanderson Cox, PhD | Completed | Missed primary |
| Phase 4 | NCT03927950 | Jan 2007 → Jan 2008 | major depressive disorder | University of Tartu | Completed | No outcome recorded |
| Phase 4 | NCT00404755 | Jul 2006 → Aug 2011 | dysthymic disorder, major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT00320697 | Apr 2006 → Oct 2008 | schizoaffective disorder, schizophrenia | North Suffolk Mental Health Association | Completed | No outcome recorded |
| Phase 4 | NCT01576640 | Dec 2005 → Oct 2007 | nicotine dependence, schizophrenia | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00611975 | Oct 2005 → May 2008 | — | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT00234195 | Sep 2005 → Jan 2007 | breast cancer, major depressive disorder | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 4 | NCT00770666 | Sep 2005 → Dec 2007 | — | University of Medicine and Dentistry of New Jersey | Completed | Met primary |
| Phase 4 | NCT00484692 | Jul 2005 → Jan 2007 | nicotine dependence, substance abuse | Medical University Innsbruck | Completed | No outcome recorded |
| Phase 4 | NCT00119210 | Mar 2005 → Mar 2006 | nicotine dependence | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00296712 | Feb 2005 → Jul 2006 | dysthymic disorder, major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT00181896 | Jan 2005 → Feb 2007 | bipolar disorder, depressive disorder | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00296777 | Dec 2004 → May 2007 | dysthymic disorder, major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT00225251 | Nov 2004 → May 2008 | dysthymic disorder | St. Luke's-Roosevelt Hospital Center | Completed | Missed primary |
| Phase 4 | NCT00316160 | Sep 2004 → May 2005 | major depressive disorder | GlaxoSmithKline | Completed | Met primary |
| Phase 4 | NCT00332644 | Sep 2004 → Aug 2010 | nicotine dependence | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 4 | NCT00186446 | Jun 2004 → Sep 2007 | major depressive disorder, nicotine dependence | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT00106197 | Jun 2004 → Mar 2014 | depressive disorder | Uma Rao | Unknown | No outcome recorded |
| Phase 4 | NCT00178828 | Oct 2002 → Apr 2013 | depressive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00044434 | May 2002 → Apr 2005 | alcohol-related disorders | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 4 | NCT00320723 | Jul 2001 → Dec 2005 | schizoaffective disorder, schizophrenia | North Suffolk Mental Health Association | Completed | No outcome recorded |
| Phase 4 | NCT00021528 | Jul 2001 → Sep 2006 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00177567 | Jul 2001 → Jan 2004 | bipolar disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00006170 | Sep 2000 → Dec 2009 | nicotine dependence | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00181818 | Oct 1999 → Dec 2003 | intermediate coronary syndrome, myocardial infarction | Massachusetts General Hospital | Completed | Met primary |
| Phase 4 | NCT00322205 | Jun 1999 → Mar 2002 | — | National Institutes of Health (NIH) | Completed | No outcome recorded |
| Phase 4 | NCT00142831 | Apr 1999 → Aug 2006 | nicotine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 4 | NCT00307203 | Aug 1998 → Feb 2004 | nicotine dependence, schizophrenia | National Institute on Drug Abuse (NIDA) | Completed | Met primary |
| Phase not applicable25 trials · 3 met primary · 2 missed | ||||||
| — | NCT07654179 | Jun 2026 → Jun 2027 expected | depressive disorder, obesity disorder | Riphah International University | Recruiting | No outcome recorded |
| — | NCT06957223 | May → Nov 2025 | major depressive disorder | Asad Ullah Jan | Completed | No outcome recorded |
| — | NCT04694846 | Aug 2020 → Aug 2024 | head and neck squamous cell carcinoma, non-small cell lung carcinoma | Thomas Jefferson University | Completed | No outcome recorded |
| — | NCT04478526 | Apr 2020 → May 2021 | generalized anxiety disorder | Dr. Nazanin Alavi | Completed | No outcome recorded |
| — | NCT04848246 | Nov 2017 → Sep 2019 | pulmonary tuberculosis | Dow University of Health Sciences | Completed | No outcome recorded |
| — | NCT03581630 | Jul 2017 → Jul 2018 | breast cancer, obesity disorder | Gangnam Severance Hospital | Completed | No outcome recorded |
| — | NCT02994082 | Dec 2016 → Sep 2019 | nicotine dependence | Mark Vander Weg | Unknown | No outcome recorded |
| — | NCT03553173 | Oct 2016 → Oct 2018 | — | Andalusian Public Foundation for Health Research in Seville | Completed | No outcome recorded |
| — | NCT02789527 | Nov 2015 → Apr 2017 | — | Estella S. Poloni | Completed | No outcome recorded |
| — | NCT02438072 | Dec 2014 → Dec 2015 | depressive disorder | University Hospital, Geneva | Unknown | No outcome recorded |
| — | NCT02317744 | Dec 2014 → Sep 2016 | binge eating disorder | Yale University | Completed | Missed primary |
| — | NCT02146911 | May 2014 → Dec 2016 | nicotine dependence | Centre for Addiction and Mental Health | Completed | Met primary |
| — | NCT02104128 | Jan 2014 → May 2016 | depressive disorder | University of Oxford | Completed | No outcome recorded |
| — | NCT01993017 | Nov 2013 → Jul 2018 | acute coronary syndrome, depressive disorder | Columbia University | Completed | Missed primary |
| — | NCT03563287 | Jan 2012 → Dec 2014 | morbid obesity | University of Eastern Finland | Completed | No outcome recorded |
| — | NCT00531518 | Oct 2007 → May 2013 | bipolar disorder, depressive disorder, schizophrenia | MaineHealth | Completed | Met primary |
| — | NCT00572234 | Aug 2007 → Apr 2010 | methamphetamine dependence | University of Nebraska | Completed | No outcome recorded |
| — | NCT00236288 | Oct 2005 → Apr 2007 | — | Indiana University | Completed | No outcome recorded |
| — | NCT00285155 | Nov 2004 → Feb 2006 | — | University Hospital, Montpellier | Completed | No outcome recorded |
| — | NCT00267813 | Jul 2004 → Oct 2007 | nicotine dependence | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| — | NCT00079469 | Feb → Aug 2004 | cancer of unknown primary site | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| — | NCT00125905 | Oct 2003 → Jul 2006 | — | Jordi Gol Institute for Primary Care Research | Unknown | Met primary |
| — | NCT01270555 | May 1999 → Jul 2001 | attention deficit-hyperactivity disorder, substance-related disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT00012558 | Sep 1998 → Sep 2005 | bipolar disorder | National Institute of Mental Health (NIMH) | Completed | Mixed |
| — | NCT00000268 | May 1995 → Nov 1998 | cocaine abuse | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Comparator or background therapy122 trials | ||||||
| Phase 0 | NCT00625131 Comparator | May 2008 → Mar 2013 | nicotine dependence, post-traumatic stress disorder | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 1 | NCT05160090 Comparator | Jan → Feb 2020 | — | Alembic Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03199339 Comparator | Aug 2017 → Jul 2018 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 1 | NCT01359930 Comparator | Aug 2011 → Jun 2012 | methamphetamine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT01046214 Comparator | Jan 2010 → ? | depressive disorder | Teva Pharmaceuticals USA | Terminated | No outcome recorded Stop: Enrollment |
| Show all 122 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 33
| Date | Issuer | Release |
|---|---|---|
| 2026-05-04 | Axsome Therapeutics, Inc. | Regulatory Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update gcs-web.com ↗
AUVELITY approved for the treatment of agitation associated with dementia due to Alzheimer’s disease |
| 2026-04-30 | Axsome Therapeutics, Inc. | Regulatory Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease gcs-web.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has approved AUVELITY ® (dextromethorphan HBr and bupropion HCl) for the treatment of agitation associated with dementia due to Alzheimer’s disease. |
| 2025-11-04 | Currax Pharmaceuticals | Results Currax Announces ObesityWeek® Data Showing that CONTRAVE® Helps Curb Cravings and Offers Marked Effectiveness in Certain Populations with Obesity curraxpharma.com ↗
Data to be presented by Dr. Robert F. Kushner, Professor Emeritus of Endocrinology, Metabolism and Molecular Medicine at Northwestern Feinberg School of Medicine, Chicago, show that treatment with CONTRAVE led to improved craving control throughout treatment when compared to placebo. |
| 2025-03-20 | Currax Pharmaceuticals | Regulatory Currax Secures Reliable and Consistent Supply of CONTRAVE®/MYSIMBA with FDA Approval for Second Manufacturing Site curraxpharma.com ↗
the U.S. Food & Drug Administration (FDA) has approved a second manufacturing site for CONTRAVE, also marketed as MYSIMBA® in the European Union and European Economic Area. |
| 2025-03-11 | Currax Pharmaceuticals | Results Currax Pharmaceuticals: Peer-Reviewed Study in Obesity Pillars Further Substantiates Cardiovascular Safety Profile of CONTRAVE®/MYSIMBA® curraxpharma.com ↗
The findings further substantiate the cardiovascular safety profile of CONTRAVE/MYSIMBA, aligning with previous clinical and observational studies. |
| 2024-08-27 | Currax Pharmaceuticals | Results Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study curraxpharma.com ↗
The results showed there is no evidence of excess cardiovascular risk and no statistically significant difference in major adverse cardiovascular events (MACE) between CONTRAVE®/MYSIMBA® and the comparator group. |
| 2024-07-24 | Currax Pharmaceuticals | Regulatory New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 Supply Issues curraxpharma.com ↗
Currax Pharmaceuticals LLC (“Currax”) today announced the approval of additional manufacturing site for CONTRAVE®/MYSIMBA® in the European Union (EU) and European Union Economic Areas (EEA). |
| 2024-05-28 | Axsome Therapeutics, Inc. | Results Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting gcs-web.com ↗
Effects of AXS-05 (Dextromethorphan-Bupropion) in Improving Anhedonia and Interest-Activity Symptoms of MDD and the Associated Improvements in Functional Impairment |
| 2023-12-11 | Axsome Therapeutics, Inc. | Results Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting gcs-web.com ↗
today announced new data that treatment with Auvelity ® (dextromethorphan-bupropion) was associated with improvement in quality of life outcomes in broad populations of depression patients in the EVOLVE open-label trial in major depressive disorder (MDD). |
| 2023-10-19 | Currax Pharmaceuticals | Results Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study curraxpharma.com ↗
Researchers found no evidence of excess cardiovascular risk and no statistically significant difference in MACE between the CONTRAVE®/MYSIMBA® group and the comparator group. |
| 2023-09-07 | Axsome Therapeutics, Inc. | Results Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023 gcs-web.com ↗
AXS-05 (Dextromethorphan-Bupropion) Significantly Improved Functioning in Major Depressive Disorder: Analysis of the Domains of the Sheehan Disability Scale |
| 2023-05-30 | Axsome Therapeutics, Inc. | Results Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting gcs-web.com ↗
The presentations on Auvelity incorporate new data and post-hoc analyses including demonstration of functional improvement in patients with major depressive disorder (MDD). |
| 2022-12-07 | Axsome Therapeutics, Inc. | Results Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annua gcs-web.com ↗
In the trial, AUVELITY rapidly, durably, and substantially improved symptoms of depression including cognitive and physical functioning, and reduced disability in patients with MDD who had received one or more prior antidepressants. |
| 2022-08-19 | Axsome Therapeutics, Inc. | Regulatory Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults gcs-web.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has approved AUVELITY TM (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD) in adults. |
| 2022-06-01 | Axsome Therapeutics, Inc. | Results Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting gcs-web.com ↗
today announced positive results from the long-term, open-label EVOLVE trial of AXS-05 (dextromethorphan-bupropion) in major depressive disorder (MDD). |
| 2022-05-31 | Axsome Therapeutics, Inc. | Results Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry gcs-web.com ↗
AXS-05 (dextromethorphan-bupropion) demonstrated rapid, substantial, and statistically significant antidepressant efficacy compared to placebo starting 1 week after treatment |
| 2022-05-18 | Axsome Therapeutics, Inc. | Results Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry gcs-web.com ↗
In this study, AXS-05 (dextromethorphan-bupropion) demonstrated rapid, substantial, and statistically significant antidepressant efficacy compared with the active comparator bupropion |
| 2021-01-14 | Alkermes, Inc. | Results NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine alkermes.com ↗
This is the second published study evaluating this combination regimen for the treatment of MUD. |
| 2020-03-30 | Axsome Therapeutics, Inc. | Results Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications gcs-web.com ↗
AXS-05 rapidly and significantly improved symptoms in patients with TRD as measured by MADRS averaged over the entire 6-week treatment period, a key secondary endpoint, with mean reductions of 8.6 for AXS-05 versus 6.7 for bupropion (p=0.031). |
| 2019-04-15 | Axsome Therapeutics, Inc. | Results Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation gcs-web.com ↗
The analysis showed that AXS-05 met the prespecified primary endpoint and significantly reduced daily smoking as compared to the active comparator bupropion. |
| 2018-12-10 | Axsome Therapeutics, Inc. | Results Axsome Therapeutics Announces Positive Outcome of Interim Analysis of ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation gcs-web.com ↗
Additionally, the IDMC recommended no further randomization of subjects to the bupropion treatment arm of the study. |
| 2018-02-26 | Axsome Therapeutics, Inc. | Results Axsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and Dextromethorphan gcs-web.com ↗ |
| 2017-04-08 | Lupin Limited | Regulatory Lupin receives FDA approval for generic Wellbutrin XL® Tablets lupin.com ↗ |
| 2016-04-22 | Pfizer | Results CHANTIX®/CHAMPIX® (varenicline) Results from the Largest Global Clinical Trial of Smoking Cessation Medicines Published in The Lancet pfizer.com ↗
The authors concluded that the trial did not show a significant increase in the incidence of the composite primary safety endpoint of serious neuropsychiatric adverse events with CHANTIX/CHAMPIX or bupropion compared to placebo and nicotine patch. |
| 2014-09-11 | Takeda | Regulatory Takeda and Orexigen Announce FDA Approval of Contrave ® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management takeda.com ↗ |
| 2012-09-03 | Wockhardt | Regulatory WOCKHARDT LAUNCHES GENERIC VERSION OF ANTIDEPRESSANT DRUG WELLBUTRIN® SR wockhardt.com ↗ |
| 2010-04-08 | Sun Pharmaceutical Industries, Inc. | Regulatory Sun Pharma announces USFDA approval for generic Wellbutrin® SR extended release tablets sunpharma.com ↗ |
| 2008-04-17 | Impax Laboratories, LLC | Results IMPAX Reports FDA Finding That Budeprion XL(R) 300 mg Is Safe and Effective amneal.com ↗
In addition, it has been shown to meet all requirements for approval, including bioequivalence to the branded drug, Wellbutrin XL(R) 300 milligram. |
| 2004-12-06 | Impax Laboratories, LLC | Regulatory IMPAX Receives Final FDA Approval and First-to-File Status for Generic Version of Wellbutrin SR 200mg Tablets; Eleventh Approval in 2004 amneal.com ↗
HAYWARD, Calif.--(BUSINESS WIRE)--Dec. 6, 2004--IMPAX Laboratories, Inc. (Nasdaq:IPXL) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval to the Company's Abbreviated New Drug Application for a generic version of Wellbutrin SR(R) (Bupropion Hydrochloride) 200mg Tablets. |
| 2004-05-27 | Impax Laboratories, LLC | Regulatory IMPAX Receives Final FDA Approval for Generic Version of Zyban; Seventh ANDA Approval in 2004 amneal.com ↗
IMPAX Laboratories, Inc. (Nasdaq:IPXL) announced that the U.S. Food and Drug Administration (FDA) has granted final marketing approval to the Company's Abbreviated New Drug Application (ANDA) for its generic version of Zyban(R), Bupropion Hydrochloride 150 mg Controlled Release Tablets. |
| 2004-03-22 | Impax Laboratories, LLC | Regulatory IMPAX Receives Final FDA Approval for Generic Version of Wellbutrin SR 150 MG amneal.com ↗ |
| 2004-01-28 | Impax Laboratories, LLC | Regulatory IMPAX Receives FDA Approval for Generic Versions of Wellbutrin SR; Final Approval Issued for the 100 mg Strength amneal.com ↗
the U.S. Food and Drug Administration (FDA) has granted final approval to the Company's Abbreviated New Drug Application (ANDA) for its generic version of Wellbutrin(R) SR (Bupropion Hydrochloride) 100 mg Controlled Release Tablets |
| 2003-05-28 | Impax Laboratories, LLC | Regulatory IMPAX ANDA Filing for Generic Version of Wellbutrin SR® 200mg Tablets Accepted by FDA amneal.com ↗
May 28, 2003 -- IMPAX Laboratories, Inc. (Nasdaq:IPXL) today announced that the United States Food and Drug Administration (FDA) has accepted the Company's filing of an Abbreviated New Drug Application (ANDA) for a generic version of Wellbutrin SR® (Bupropion Hydrochloride) 200mg Tablets. |
All press releases naming this drug 50 releases
Evidence & citations 35 cited values
Every value below carries the sentence it was read from. 397 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bupropion | “we randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive...” PMID 16554525 ↗ Mar 2006377“If the patient has been deemed unresponsive to both an SSRI and an SNRI/pregabalin, the patient will commence the secondary medication arm. The two classes of medications...” NCT04478526 ↗ “Nirogacestat 100 mg BID will be administered orally from Day 1 through Day 17 and an oral dose of CYP cocktail (CYP2B6 [bupropion 20 mg], CYP2C8 [repaglinide 0.05 mg], CYP2C9...” NCT07259330 ↗ “Patients will receive ECT treatment as usual, but for this study if they choose to participate they will be randomized to receive bupropion (sustained release preparation 300...” NCT03126682 ↗ “Two equally loaded capsules containing: Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone...” NCT03563287 ↗ “In this DDI part, each subject (n=14) will be administered midazolam (2 mg suspension) and bupropion (150 mg, tablet) together on Day 1, followed by a 7-day washout, followed...” NCT03199339 ↗ “we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These...” NCT02458690 ↗ “Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗ “Ten volunteers received an oral cocktail capsule containing low doses of the probes bupropion (CYP2B6), flurbiprofen (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6),...” PMID 24722393 ↗ Apr 2014 “ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its...” NCT01838876 ↗ “Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine,...” NCT02400346 ↗ |
| Known as | 323U66 | “Clinical Evaluation of Bupropion SR (323U66)in Patients With Depression - Investigation in Elderly Patients With Depression” NCT00330616 ↗1“323U66 (Bupropion Hydrochloride Sustained Release)” NCT00296517 ↗ |
| Known as | amfebutamone | “bupropion_amfebutamone, Wellbutrin, Zyban” NCT00817011 ↗ |
| Known as | BRP | “once-daily oral extended-release bupropion (BRP, Welbutrin XL, 450 mg/day)” PMID 30724759 ↗ Sep 2019 |
| Known as | BUP | “The purpose of this study is to determine the effectiveness of bupropion SR (commonly known as Zyban) in combination with a nicotine transdermal patch (NTP), in helping...” NCT00124683 ↗6“A randomized, double-blind, parallel-group double-dummy study evaluated two medications, bupropion (BUP) and naltrexone (NTX), in treatment-seeking cigarette smokers” PMID 27213949 ↗ Jun 2016 “sustained release (SR) Bupropion (BUP) and immediate release (IR) Dextromethorphan (DXM)” NCT03471767 ↗ “A combination of bupropion (BUP) and naltrexone (NTX) is effective for obesity.” NCT01739192 ↗ “initially treated with a combination of escitalopram (ESC) plus bupropion (BUP)” PMID 19820552 ↗ Sep 2009 “bupropion (BUP), a nonserotonergic antidepressant” NCT01407094 ↗ “bupropion SR (BUP)” NCT01048944 ↗ |
| Known as | BUP-SR | “In phase two, participants are offered an 8-week course of bupropion-sustained release (BUP-SR).” NCT02162862 ↗ |
| Known as | BUP-XL | “Participants will begin the 12 week medication phase of the trial. Participants will be randomized to either the 1) AMC arm and receive injections of extended release...” NCT03078075 ↗1“extended release bupropion (BUP-XL) tablets (BUP-XL)” NCT06233799 ↗ |
| Known as | Bupropion extended release | “Patients (N = 245) meeting criteria for major depressive disorder (MDD), diagnosed with DSM-IV-TR, were randomly assigned to double-blind treatment with bupropion...” PMID 25295437 ↗ Sep 20142“bupropion extended release (Wellbutrin XL)” NCT00234195 ↗ “Drug: Bupropion extended release” NCT01477931 ↗ |
| Known as | Bupropion HCI | “The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 300 mg ER Tablets under fasting conditions.” NCT00861939 ↗2“WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline” NCT06675851 ↗ “Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.” NCT00864981 ↗ |
| Known as | Bupropion HCl | “Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week,...” NCT03581630 ↗9“The drug being tested in this study is naltrexone HCl and bupropion HCl Extended- Release fixed dose combination (NB) .” NCT02745912 ↗ “Use of smoking cessation pharmacotherapy such as Zyban (bupropion HCl) has been shown to double quit rates” NCT01015170 ↗ “Naltrexone HCl 8 mg/bupropion HCl 90 mg tablets” NCT02616315 ↗ “Bupropion HCl 100 mg Tablets (Invamed Inc.)” NCT00883155 ↗ “Bupropion HCl 300mg Extended Release Tablet” NCT00861939 ↗ “bupropion HCL (brand name Zyban)” NCT00322205 ↗ “Bupropion HCl XL tablet 300mg” NCT02698553 ↗ |
| Known as | bupropion hydrobromide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02129751 ↗ |
| Known as | bupropion hydrochloride | “Bupropion hydrochloride will be administered orally as a single dose as one 150 milligrams (mg) tablet with 240 milliliters of water (fasting).” NCT04526210 ↗9“The purpose of the study is to evaluate the effects of a single-dose of Wellbutrin XL (bupropion hydrochloride) on reward processing.” NCT00205946 ↗ “Extended-release Bupropion Hydrochloride (Bupropion XL) Tablets 150 mg and 300 mg Once Daily in Chinese Healthy Volunteers” NCT02698553 ↗ “The drug being tested in this study is called naltrexone hydrochloride/bupropion hydrochloride (NB).” NCT02616315 ↗ “Drug: bupropion hydrochloride” NCT00033592 ↗ |
| Known as | Bupropion hydrochloride (HCl) | “Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week,...” NCT03581630 ↗ |
| Known as | Bupropion Hydrochloride ER | “Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)” NCT06098079 ↗ |
| Known as | bupropion hydrochloride extended release | “A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of...” NCT00316160 ↗3“The aims of this study are 1) to examine the clinical utility of bupropion hydrochloride extended release (Wellbutrin XL®) in patients with Major Depressive Disorder (MDD) with...” NCT01477931 ↗ “Bupropion Hydrochloride Extended Release is administered orally three times a week during routine dialysis sessions for 8 consecutive weeks” NCT06609343 ↗ “Drug: Bupropion Hydrochloride Extended-release” NCT07398404 ↗ |
| Known as | Bupropion Hydrochloride Sustained Release | “323U66 (Bupropion Hydrochloride Sustained Release)” NCT00296517 ↗ |
| Known as | Bupropion XL | “Mothers of healthy infants who quit smoking while pregnant will be stratified based on current or past history of major depressive disorder or persistent depressive disorder...” PMID 33706003 ↗ Mar 20215“In this double-blind, multicenter study, bupropion XL, a norepinephrine-dopamine reuptake inhibitor, and venlafaxine XR, a serotonin-norepinephrine reuptake inhibitor, were...” PMID 16974189 ↗ Oct 2006 “Patients randomized to the bupropion treatment group will receive bupropion XL150 mg in the AM for 7 days increasing to 300mg/day (single daily dose).” NCT00248209 ↗ “Extended-release Bupropion Hydrochloride (Bupropion XL) Tablets 150 mg and 300 mg Once Daily in Chinese Healthy Volunteers” NCT02698553 ↗ “Standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) dispensed by the UNC Investigational Drug Services.” NCT02842073 ↗ “extended-release bupropion (bupropion XL)” PMID 16848645 ↗ Jun 2006 |
| Known as | Bupropion, Wellbutrin | “bupropion = Wellbutrin” NCT00296712 ↗1“Bupropion, Wellbutrin” NCT01916824 ↗ |
| Known as | bupropion-SR | “A randomized, double-blind, parallel group design will be used to allow a rigorous preliminary assessment of the feasibility, effectiveness, and safety of bupropion SR...” NCT01286402 ↗11“Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗ “Participants will receive Bupropion SR (Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour...” NCT03471767 ↗ “bupropion SR (sustained-release) are non nicotine pharmacotherapies FDA-indicated for the treatment of tobacco dependence in cigarette smokers.” NCT00935818 ↗ “Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release).” NCT02162862 ↗ “combined naltrexone sustained-release (SR) (32 mg/day) plus bupropion SR (360 mg/day) (NB32) or placebo” PMID 23408728 ↗ May 2013 “naltrexone sustained-release (SR, 32 mg/day), combined with bupropion SR (360 mg/day) plus BMOD” PMID 20559296 ↗ Jun 2010 “Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)” NCT01764386 ↗ “Naltrexone SR 32 mg/bupropion SR 360 mg/ day” NCT00474630 ↗ “100mg of Bupropion SR in the morning” NCT00296517 ↗ “Bupropion SR 150 mg tablet” NCT01390246 ↗ |
| Known as | bupropion-Sustained Release | “Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release).” NCT02162862 ↗ |
| Known as | buproprion | “Buproprion (Wellbutrin) works on dopamine and the dopaminergic pathway.” NCT00001483 ↗ |
| Known as | Welbutrin XL | “once-daily oral extended-release bupropion (BRP, Welbutrin XL, 450 mg/day)” PMID 30724759 ↗ Sep 2019 |
| Known as | Wellbutrin | “Patients will receive ECT treatment as usual, but for this study if they choose to participate they will be randomized to receive bupropion (sustained release preparation 300...” NCT03126682 ↗8“Bupropion (a medication marketed as Wellbutrin or Zyban) has proved helpful in treating adult smokers.” NCT00129272 ↗ “the sustained release (SR) and extended release (XL) medication bupropion (Wellbutrin®)” NCT02173886 ↗ “Participants will be prescribed varenicline (Chantix) or bupropion (Wellbutrin).” NCT04490057 ↗ “Buproprion (Wellbutrin) works on dopamine and the dopaminergic pathway.” NCT00001483 ↗ “bupropion_amfebutamone, Wellbutrin, Zyban” NCT00817011 ↗ “time-released bupropion (Wellbutrin)” NCT00044434 ↗ “bupropion (Wellbutrin and others)” NCT01944657 ↗ |
| Known as | WELLBUTRIN SR | “Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗4“The purpose of this study is to understand changes in brain chemical signals when people take antidepressants called sertraline (Zoloft®) and bupropion (Wellbutrin SR, Zyban ®).” NCT00178828 ↗ “Sustained release (SR) bupropion (Zyban, Wellbutrin SR) is a non-nicotine antidepressant drug” NCT00181818 ↗ “WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline” NCT00864981 ↗ “WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline” NCT06675851 ↗ |
| Known as | Wellbutrin XL | “A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of...” NCT00316160 ↗3“bupropion extended-release tablets (BRP; as Wellbutrin XL®)” NCT01982643 ↗ “bupropion extended release (Wellbutrin XL)” NCT00234195 ↗ “Bupropion: Wellbutrin XL®” NCT03078075 ↗ |
| Known as | Wellbutrin, bupropion | “Wellbutrin, bupropion” NCT00126373 ↗ |
| Known as | Zyban | “The purpose of this study is to determine the effectiveness of bupropion SR (commonly known as Zyban) in combination with a nicotine transdermal patch (NTP), in helping...” NCT00124683 ↗8“The purpose of this study is to understand changes in brain chemical signals when people take antidepressants called sertraline (Zoloft®) and bupropion (Wellbutrin SR, Zyban ®).” NCT00178828 ↗ “This is an open label study, wherein eligible participants will be randomized to receive bupropion (Zyban®) or varenicline (Champix®) for 12 weeks” NCT02146911 ↗ “We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban).” NCT00267813 ↗ “Bupropion (a medication marketed as Wellbutrin or Zyban) has proved helpful in treating adult smokers.” NCT00129272 ↗ “Sustained release (SR) bupropion (Zyban, Wellbutrin SR) is a non-nicotine antidepressant drug” NCT00181818 ↗ “Bupropion SR 150mg tabs (Zyban) twice daily” NCT00994448 ↗ “bupropion_amfebutamone, Wellbutrin, Zyban” NCT00817011 ↗ “bupropion HCL (brand name Zyban)” NCT00322205 ↗ |
| Known as | Zyban SR | “Bupropion's (Zyban(®) SR) effectiveness to treat symptoms experienced in marihuana withdrawal was tested in a double-blind, placebo-controlled study with chronic, heavy marihuana users.” PMID 22879754 ↗ Jun 20121“Bupropion (Zyban SR)” NCT00063323 ↗ |
| Known as | Zyban Sustained Release | “Bupropion (brand name Zyban Sustained Release).” NCT00063323 ↗ |
| Known as | Zyban(R) | “sustained-release bupropion (Zyban(R))” NCT00484692 ↗ |
| Known as | Zyntabac | “Usual pharmacological therapy consists of bupropion (Zyntabac 150 mg) or varenicline (Champix 0.5 mg or 1 mg).” PMID 30522992 ↗ Dec 2018 |
| Action | Inhibit | “The antidepressant Bupropion is a dopamine and norepinephrine reuptake inhibitor.” NCT01047254 ↗ |
| Modality | Small molecule | “Bupropion, an amphetamine derivative” NCT00133757 ↗ |
| Route | Oral | “Patients receive oral bupropion once daily on days 1-3 and twice daily on days 4-77.” NCT00032084 ↗ |
| Target | TNF | “The investigators will also be looking to see if Wellbutrin can lower levels of the inflammatory cytokine tumor necrosis factor-alpha (TNF).” NCT00126373 ↗ |